Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sinsin Pharmaceutical Co., Ltd. (002800:KRX), powered by AI.
Sinsin Pharmaceutical Co., Ltd. is currently trading at ₩4,725. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Sinsin Pharmaceutical Co., Ltd. on Alpha Lenz.
Sinsin Pharmaceutical Co., Ltd.'s P/E ratio is 7.7.
“Sinsin Pharmaceutical Co., Ltd. trades at a P/E of 7.7 (undervalued) with solid ROE of 13.2%.”
Ask for details →Sinsin Pharmaceutical Co., Ltd. is a prominent entity in the healthcare sector, primarily engaged in the production and distribution of pharmaceutical products. Focused on delivering high-quality medication, the company dedicates itself to researching and developing innovative solutions that address various health conditions. Its product lineup includes prescription drugs, over-the-counter remedies, and therapeutic pharmaceuticals designed to meet diverse consumer health needs. Sinsin Pharmaceutical operates within industries such as healthcare, biotechnology, and medical supplies, impacting both domestic and international markets through its widespread distribution channels. As a vital component of the pharmaceutical industry, the company plays a significant role in enhancing global health standards by ensuring accessibility to essential medications and fostering advancements in medical treatment. Headquartered in South Korea, Sinsin Pharmaceutical continues to contribute to the healthcare landscape with a commitment to quality assurance and regulatory compliance, positioning itself as a trusted provider within the medical community.
“Sinsin Pharmaceutical Co., Ltd. trades at a P/E of 7.7 (undervalued) with solid ROE of 13.2%.”
Ask for details →Sinsin Pharmaceutical Co., Ltd. (ticker: 002800) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 356 employees. Market cap is $71.7B.
The current price is ₩4,725 with a P/E ratio of 7.71x and P/B of 0.96x.
ROE is 13.21% and operating margin is 9.48%. Annual revenue is $113.8B.